Whilst autologous stem cell transplantation (auto-SCT) is considered standard of care for relapsed/ refractory classical Hodgkin lymphoma, the role of auto-SCT in nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) is not well defined due to limited data. We report the first study on auto-SCT for NLPHL with a larger cohort. Eligible for this retrospective registry study were patients reported to the EBMT between 2003 and 2013, aged 18 or older with relapsed/refractory NLPHL who underwent first auto-SCT with disease chemosensitive to salvage therapy. NLPHL transformed to diffuse large B cell lymphoma were excluded. Sixty patients (83% male; median age 40 years) met the eligibility criteria. The median time between diagnosis and transplant was 21 months (IQR 13-58), and the median number of prior treatment lines was 2 (range 1-5), including rituximab in 63% of the patients. At auto-SCT, 62% of the patients were in complete remission (CR) and 38% in partial remission. Seventy-two percent of the patients received BEAM as highdose therapy. With a median follow-up of 56 months (range 3-105), 5-year progression-free and overall survival (OS) were 66% and 87%, respectively. Univariate comparisons considering age, time from diagnosis to transplant, prior chemotherapy lines, and prior rituximab use failed to identify significant predictors for any survival endpoint except for being in CR at the time of auto-SCT (vs PR, P 5 .049) for OS. Auto-SCT in patients with relapsed/refractory NLPHL who are sensitive to salvage therapy gives excellent disease control and long-term survival independent of the time interval between diagnosis and transplant.
| P A TI EN TS

| Study design
This was a retrospective EBMT registry-based analysis. Eligible for this study were patients aged 18 or older with relapsed NLPHL who underwent a first auto-SCT between 2003 and 2013 and were reported to the EBMT. Patients with refractory disease (not responding to salvage chemotherapy) at auto-SCT and those with NLPHL transformed to DLBCL were not eligible (in the registry data, these NLPHL patients transformed to DLBCL are captured as DLBCL as the final diagnosis requiring auto-SCT). Baseline patient, disease, and transplant data were collected from EBMT MED-A standard forms. Centers with potentially eligible patients were contacted to provide additional treatment details, follow-up information, and a copy of the written histopathology report for "central review." As per registry practice, response was accepted as reported without further inquiries related to the criteria used for the response.
| Statistical analysis
Primary end-point was 5-year progression free survival (PFS) defined as the time from auto-SCT to disease relapse or progression or death from any cause, whichever came first. Secondary endpoints were overall survival (OS), defined as the time from auto-SCT to death from any cause, relapse incidence (RI), and nonrelapse mortality, defined as the time from auto-SCT to death in the absence of prior relapse or progression.
Univariate and multivariate analyses to study the association of patient, disease and transplant variables with outcome were performed.
Survival curves for OS and PFS were estimated by the Kaplan Meier method and compared between groups using the log-rank test. The following prognostic factors were considered: age, sex, remission status at auto-SCT (complete remission, CR vs. PR as reported/provided by the participating centers), type of high-dose therapy and use of rituximab prior to transplant. All analyses were done using R version 3. 2014. R Foundation for Statistical Computing, Vienna, Austria). All statistical tests were 2-sided with a P value <.05 considered to indicate a statistically significant result.
| RE S U L TS
| Patients
A total of 374 patients were identified in the EBMT registry meeting the eligibility criteria for this study. These centers were contacted to participate in this study. Additional information upon request was provided for 105 of 374 patients. Of these, 39 patients had to be excluded after histopathology review (17 classical HL, 2 NHL, 20 not informative), and 6 patients were excluded based on disease status at auto-SCT (2 primary induction failure/refractory to chemotherapy, 4 refractory relapses), leaving 60 patients in the final study sample, 50 (83%) of them being male. 
| Outcome
When comparing the outcome of the 60 patients included with that of the 220 patients who were not included because of missing verification of diagnosis and/or baseline data, we found an inferior outcome for 
| Prognostic factors
On univariate analysis, patients who underwent auto-SCT in PR had a significantly shorter OS than those patients who were transplanted in precluding valid conclusions. 7, [11] [12] [13] 15, 16 Here, we report the largest cohort of patients with NLPHL who underwent auto-SCT for relapsed or refractory disease, after responding to salvage therapy. With a 5-year PFS and OS of 66% and 87%, respectively, the long-term outcome appears to be much better than that of auto-SCT in relapsed/refractory classical HL [17] [18] [19] and other B-cell lymphomas, [20] [21] [22] suggesting an excellent sensitivity of NLPHL to high-dose chemotherapy (Table 2 ).
In spite of limitations, like the selection bias inevitably associated with a retrospective registry study reporting on patients who have received an auto-SCT, failure to get a response from non-participating centers on large number of patients, diverse managements/salvage chemotherapy, these patients had high-risk features. Although almost all the patients received anthracycline-based primary chemotherapy, half of the patient's disease did not enter into CR, 1/3 of the patients had received 3 or more lines of therapy and 2/3 had received rituximab; in addition, the majority of the patients had advanced disease at diagnosis and 1/3 also had B-symptoms. These poor risk features are not commonly reported in patients with NLPHL. We have not included patients with DLBCL transformed from NLPHL The registry.
Our data are consistent with the results of the two case series on auto-SCT in NLPHL fully published to date. Karuturi et al. 13 In our report, we have observed that patients with NLPHL undergoing auto-SCT with measurable residual disease (PR only after salvage chemotherapy) had a significantly poorer OS than those in CR. Since this was not due to a PFS disadvantage of the same size, it appears that patients not completely responding to salvage therapy prior to transplant are more difficult to rescue in case of disease recurrence post transplant. However, we were not able to detect a significant effect of any other variable on any survival endpoint. This included rituximab pre-exposure, a factor that had shown some beneficial effect on PFS in one of the previous case series 11 and the time between diagnosis and auto-SCT. 
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